With a deep understanding of the complex mechanisms underlying gastric mucosal injury and repair, Ace Therapeutics is committed to delivering effective solutions to advance the development of mucosal protective agents (MPAs) for gastrointestinal health. We leverage our knowledge of mucosal immunology and biology, inflammation, and wound healing to identify and develop agents that strengthen the mucosal barrier, reduce inflammation, and promote tissue regeneration.
Introduction to Gastric Mucosa
The gastric mucosa plays a crucial role in nutrient absorption, protection, and immune defense. It forms a barrier against pathogens and toxins, while secreting mucus and bicarbonate to protect against gastric acid. Tight junctions between epithelial cells prevent harmful substances from entering the bloodstream. Damage to the gastric mucosa can result from various factors such as infections, toxins, and inflammatory conditions, leading to diseases such as ulcers and inflammatory bowel disease.
Figure 1. HE staining results of ileal mucosa in rats after treatment with mucosal protective agents. (Satoh H., et al., 2014)
Types of Gastric Mucosal Protective Agents We Can Develop
- Development of Exogenous Mucosal Protective Agents
Ace Therapeutics provides a full range of services to support the development of novel exogenous mucosal protection agents, including aluminum, magnesium, and bismuth compounds. Through formulation optimization, we can help you develop optimized oral and topical dosage forms to precisely deliver these active agents to the mucosal surface. Our disease models can be used to characterize the mechanisms of action of your candidates in maintaining barrier integrity and promoting repair.
-
Development of Endogenous Mucosal Protective Agents
We offer extensive capabilities to support the development of innovative endogenous mucosal protective agents such as prostaglandins and their derivatives. With expertise in lead screening optimization, we assist in designing stable prostaglandin analogs and modulators of prostaglandin targets with optimized pharmacokinetic and tissue selectivity profiles. Our experts can conduct comprehensive preclinical assessments including assays to elucidate enhancement of mucosal integrity, resolution of inflammation, and repair of the epithelial barrier repair.
What Can We Do for the Development of Gastric Mucosal Protective Agents?
In Vitro Studies
In Vivo Studies
We utilize various cell culture models, including human intestinal epithelial cell lines (e.g., Caco-2, HT-29) and gastric epithelial cell lines (e.g., AGS, GES-1), to assess the protective effects of agents on the mucosal barrier.
- Transepithelial Electrical Resistance (TEER) Measurement: Assess the electrical resistance across a cell monolayer, indicating barrier integrity.
- Permeability Assays: Measure the passage of fluorescent markers or macromolecules across the cell monolayer, indicating barrier permeability.
- Mucin Production Assays: Measure the production of mucin, the primary component of mucus.
- DPPH Radical Scavenging Assays: Measure the ability of the agent to neutralize free radicals.
- ABTS Decolorization Assays: Assess the ability of the agent to scavenge free radicals.
Ace Therapeutics offers comprehensive services for in vivo efficacy studies of mucosal protective agents. We customize the most appropriate animal model for your specific research needs, considering factors such as disease type, severity, and relevant physiological parameters.
- Indomethacin-induced gastric ulcer models: Assess the efficacy of agents in preventing or healing gastric ulcers.
- Dextran sulfate sodium (DSS)-induced colitis models: Evaluate the efficacy of agents in reducing colitis severity and promoting mucosal healing.
- Other models: We can also utilize other models, such as the TNBS-induced colitis model, depending on your specific research needs.
Ace Therapeutics specializes in providing comprehensive services for the development of mucosal protective agents, addressing the challenges associated with gastrointestinal health. Contact us today to discuss your specific needs and explore how our services can accelerate your development program.
Reference
- Satoh H., et al. Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats. J Pharmacol Exp Ther. 2014, 348(2):227-35.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
